Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

Hypertension Clinical Trial

— HFpEF-PRoF  

Official title:

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02589977
• Other study ID #: 141686
• Status: Completed
• Phase: Phase 4
• Start date: November 2015
• Est. completion date: January 21, 2020

Study information

• Verified date: February 2021
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Unlike heart failure with reduced ejection fraction (HFrEF) where several medicines and devices have been demonstrated to reduce mortality, no such therapies have been identified in HFpEF. This may be in part due to incomplete understanding of the underlying mechanisms of HFpEF. Recently, impaired myocardial blood flow, reduced myocardial energy utilization, and increased myocardial fibrosis have been postulated to play important pathophysiologic roles in HFpEF. The investigators and others have demonstrated that HFrEF may be associated with altered myocardial energy utilization and "energy starvation." However, there are limited data regarding "energy starvation" in HFpEF and the relationships between myocardial blood flow, energy utilization, and fibrosis in HFpEF are largely unknown. Therefore, the purposes of this study are to use non-invasive cardiac imaging techniques to describe cardiac structure, function, blood flow, energetics, and fibrosis, and the relationships between these in order to better understand underlying mechanisms in HFpEF.

Description:

The investigators hypothesize that HFpEF is associated with reductions in myocardial blood flow and energy utilization and increased myocardial fibrosis as compared to age and gender matched hypertensive and healthy controls. The investigators will test their hypotheses by comparing measurements of myocardial blood flow, energy utilization, and fibrosis between three subject groups (HFpEF vs hypertension vs healthy). Myocardial blood flow will be quantitated from nitrogen (N)13-Ammonia positron emission tomography (PET) and gadolinium enhanced cardiac magnetic resonance (CMR) imaging, both at rest and stress following coronary vasodilation with regadenoson. Myocardial energy utilization will be quantified with 11C-acetate PET imaging and myocardial fibrosis will be assessed with gadolinium enhanced CMR and alterations in myocardial T1. Echocardiography will be utilized to quantify cardiac diastolic function. It is anticipated that the results of this proposed study will provide a foundation that will inform future studies aimed at identifying novel preventive or therapeutic agents in HFpEF.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: January 21, 2020
• Est. primary completion date: January 21, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

ALL

Inclusion Criteria:

• estimated glomerular filtration rate (eGFR) > 60 ml/min
• preserved left ventricular ejection fraction (>= 50%) on echocardiography

Exclusion Criteria:

• coronary artery disease
• diabetes mellitus
• contraindications to cardiac magnetic resonance imaging (CMR)
• weight >350 lbs
• inability to lie flat for imaging
• anemia
• contraindications to regadenoson or aminophylline HEALTHY

Inclusion criteria:

• normal cardiac structure and function on echocardiography
• BP < 140/90

Exclusion criteria:

• known cardiovascular disease, cardiac risk factors or use of cardiac medications HYPERTENSIVE

Inclusion criteria:

• history of BP >140/90
• 1 or more antihypertensive medications
• LV ejection fraction (LVEF) at least 50%
• current BP < 160/90

Exclusion criteria:

• known cardiovascular disease or risk factors aside from hypertension or use of cardiac medications HFpEF

Inclusion criteria:

• physician-confirmed diagnosis of HF
• symptomatic HF
• LVEF at least 50%
• elevated LV filling pressure by catheterization, echocardiographic criteria or B-type-natriuretic peptide > 100
• current BP < 160/90

Exclusion criteria:

• prior history of LVEF below 50%
• acute decompensated HF
• moderate or greater valvular disease
• significant cardiac arrhythmias
• pericardial disease
• congenital heart disease
• primary pulmonary hypertension

Related Conditions & MeSH terms

• Diastolic Heart Failure
• Heart Failure
• Heart Failure, Diastolic
• Hypertension

Intervention

Drug:
• regadenoson
evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Marvin W. Kronenberg, M.D.	Astellas Pharma US, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Bell SP, Adkisson DW, Ooi H, Sawyer DB, Lawson MA, Kronenberg MW. Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy. J Card Fail. 2013 Dec;19(12):802-10. doi: 10.1016/j.cardfail.2013.10.010. Epub — View Citation

Gupta DK, Shah AM, Castagno D, Takeuchi M, Loehr LR, Fox ER, Butler KR, Mosley TH, Kitzman DW, Solomon SD. Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study. JACC Heart Fail. 2013 Apr — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Coronary Flow Reserve	Rest and regadenoson stress coronary flow reserve by ammonia PET. Coronary flow calculated at rest and again at stress with coronary flow reserve calculated as the ratio of stress to rest coronary flow.	Baseline study visit
Secondary	Myocardial Perfusion Reserve by CMR in Each Study Group.	Myocardial perfusion reserve by CMR.	Baseline study visit.
Secondary	Extracellular Volume (ECV) by CMR in Each Study Group	Extracellular volume (ECV) by CMR.	Baseline study visit
Secondary	Oxidative Metabolism (Kmono/Rate Pressure Product) by PET in Each Study Group.	Oxidative metabolism (Kmono/rate pressure product) by PET.	Baseline study visit
Secondary	E/e' by Echo in Each Study Group.	E/e' by echo. E is the transmitral peak velocity in early diastole. e' is the early diastolic tissue Doppler velocity average between the septal and lateral mitral annulus. E/e' is the ratio of these two values.	Baseline study visit